APOE and neoplasm: In the 4 T1 murine BC model, combined APOE inhibitor and ICI therapy exhibited optimal anti‐tumor effects, suggesting that targeting APOE+ macrophages could potentially enhance the therapeutic efficacy of ICIs [13].